Literature DB >> 31119568

Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.

Erik Hedrick1,2, Xi Li1, Yating Cheng1,3, Alexandra Lacey4, Kumaravel Mohankumar1, Mahsa Zarei1, Stephen Safe5.   

Abstract

BACKGROUND: Nuclear receptor 4A1 (NR4A1) is overexpressed in mammary tumors, and the methylene-substituted bis-indole derivative 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) acts as an NR4A1 antagonist (inverse agonist) and inhibits NR4A1-regulated pro-oncogenic pathways/genes in breast and other cancer cells.
METHODS: Buttressed analogs of DIM-C-pPhOH were synthesized by condensation of the substituted p-hydroxybenzaldehydes with indole. Breast cancer cell growth, survival, and migration assays were carried out by cell counting, Annexin V staining, and Boyden chamber assays, respectively. Changes in RNA and protein expression were determined by RT-PCR and western blots, respectively. Analysis of RNAseq results was carried out using Ingenuity Pathway Analysis, and in vivo potencies of NR4A1 antagonists were determined in athymic nude mice bearing MDA-MB-231 cells in an orthotopic model.
RESULTS: Ingenuity Pathway analysis of common genes modulated by NR4A1 knockdown or treatment with DIM-C-pPhOH showed that changes in gene expression were consistent with the observed decreased functional responses, namely inhibition of growth and migration and increased apoptosis. DIM-C-pPhOH is rapidly metabolized and the effects and potencies of buttressed analogs of DIM-C-pPhOH which contain one or two substituents ortho to the hydroxyl groups were investigated using NR4A1-regulated gene/gene products as endpoints. The buttressed analogs were more potent than DIM-C-pPhOH in both in vitro assays and as inhibitors of mammary tumor growth. Moreover, using 1,1-bis(3'-indolyl)-1-(3-chloro-4-hydroxy-5-methoxyphenyl)methane (DIM-C-pPhOh-3-Cl-5-OCH3) significant tumor growth inhibition was observed at doses as low as 2 mg/kg/d which was at least an order of magnitude more potent than DIM-C-pPhOH.
CONCLUSIONS: These buttressed analogs represent a more potent set of second generation NR4A1 antagonists as inhibitors of breast cancer.

Entities:  

Keywords:  Antagonists; Anticancer activities; NR4A1; bis-indole ligands

Mesh:

Substances:

Year:  2019        PMID: 31119568      PMCID: PMC6681651          DOI: 10.1007/s10549-019-05279-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

Review 1.  Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

Authors:  V Craig Jordan
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

2.  Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions.

Authors:  Susan Holbeck; Jianjun Chang; Anne M Best; Angie L Bookout; David J Mangelsdorf; Elisabeth D Martinez
Journal:  Mol Endocrinol       Date:  2010-04-07

3.  Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways.

Authors:  Sung Dae Cho; Kyungsil Yoon; Sudhakar Chintharlapalli; Maen Abdelrahim; Ping Lei; Stanley Hamilton; Shaheen Khan; Shashi K Ramaiah; Stephen Safe
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

4.  Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth.

Authors:  Syng-Ook Lee; Maen Abdelrahim; Kyungsil Yoon; Sudhakar Chintharlapalli; Sabitha Papineni; Kyounghyun Kim; Huamin Wang; Stephen Safe
Journal:  Cancer Res       Date:  2010-07-21       Impact factor: 12.701

5.  Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.

Authors:  Annika N Alexopoulou; Maria Leao; Otavia L Caballero; Leonard Da Silva; Lynne Reid; Sunil R Lakhani; Andrew J Simpson; John F Marshall; A Munro Neville; Parmjit S Jat
Journal:  Breast Cancer Res       Date:  2010-07-19       Impact factor: 6.466

6.  Stereochemical and steric control of the UDP-glucuronosyltransferase-catalyzed conjugation reaction: a rational approach for the design of inhibitors for the human UGT2B7.

Authors:  Ingo Bichlmaier; Moshe Finel; Wolfgang Sippl; Jari Yli-Kauhaluoma
Journal:  ChemMedChem       Date:  2007-12       Impact factor: 3.466

Review 7.  SERMs: meeting the promise of multifunctional medicines.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2007-03-07       Impact factor: 13.506

8.  Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer.

Authors:  Yangsik Jeong; Yang Xie; Guanghua Xiao; Carmen Behrens; Luc Girard; Ignacio I Wistuba; John D Minna; David J Mangelsdorf
Journal:  PLoS Med       Date:  2010-12-14       Impact factor: 11.069

9.  The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53.

Authors:  S-O Lee; T Andey; U-H Jin; K Kim; M Singh; M Sachdeva; S Safe
Journal:  Oncogene       Date:  2011-11-14       Impact factor: 9.867

10.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

View more
  10 in total

1.  Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.

Authors:  Erik Hedrick; Kumaravel Mohankumar; Alexandra Lacey; Stephen Safe
Journal:  Mol Cancer Res       Date:  2019-08-28       Impact factor: 5.852

2.  Pharmacological activation of Nr4a rescues age-associated memory decline.

Authors:  Snehajyoti Chatterjee; Emily N Walsh; Amy L Yan; K Peter Giese; Stephen Safe; Ted Abel
Journal:  Neurobiol Aging       Date:  2019-10-14       Impact factor: 4.673

3.  Nuclear receptor 4A1 (NR4A1) antagonists target paraspeckle component 1 (PSPC1) in cancer cells.

Authors:  Kumaravel Mohankumar; Rupesh Shrestha; Stephen Safe
Journal:  Mol Carcinog       Date:  2021-10-26       Impact factor: 4.784

4.  3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial.

Authors:  Rinat Yerushalmi; Sharon Bargil; Yaara Ber; Rachel Ozlavo; Tuval Sivan; Yael Rapson; Adi Pomerantz; Daliah Tsoref; Eran Sharon; Opher Caspi; Ahuvah Grubsrein; David Margel
Journal:  Carcinogenesis       Date:  2020-10-15       Impact factor: 4.944

5.  Gut bacterial metabolites modulate endoplasmic reticulum stress.

Authors:  Xiaobo Ke; Kwontae You; Matthieu Pichaud; Henry J Haiser; Daniel B Graham; Hera Vlamakis; Jeffrey A Porter; Ramnik J Xavier
Journal:  Genome Biol       Date:  2021-10-15       Impact factor: 13.583

Review 6.  3,3'-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs.

Authors:  Bernhard Biersack
Journal:  Cancer Drug Resist       Date:  2020-10-12

Review 7.  Therapeutic potential of NR4A1 in cancer: Focus on metabolism.

Authors:  Shan Deng; Bo Chen; Jiege Huo; Xin Liu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

8.  NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth.

Authors:  Keshav Karki; Kumaravel Mohankumar; Abigail Schoeller; Gregory Martin; Rupesh Shrestha; Stephen Safe
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

Review 9.  The Paradoxical Roles of Orphan Nuclear Receptor 4A (NR4A) in Cancer.

Authors:  Stephen Safe; Keshav Karki
Journal:  Mol Cancer Res       Date:  2020-10-26       Impact factor: 6.333

10.  NR4A1 Deletion in Marginal Zone B Cells Exacerbates Atherosclerosis in Mice-Brief Report.

Authors:  Meritxell Nus; Gemma Basatemur; Maria Galan; Laia Cros-Brunsó; Tian X Zhao; Leanne Masters; James Harrison; Nichola Figg; Dimitrios Tsiantoulas; Frederic Geissmann; Christoph J Binder; Andrew P Sage; Ziad Mallat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 10.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.